Celecoxib and radioresistant glioblastoma-derived CD133+ cells: improvement in radiotherapeutic effects

Abstract

Celecoxib combined with radiation plays a critical role in the suppression of growth of CD133(+) glioblastoma stemlike cells. Celecoxib is therefore a radiosensitizing drug for clinical application in glioblastoma.